US FDA requires Lilly to conduct post-marketing studies for obesity pill
US FDA requires Lilly to conduct post-marketing studies for obesity pill
ReutersTue, April 14, 2026 at 12:42 PM UTC
0
FILE PHOTO: A bottle of Eli Lilly’s Foundayo weight-loss pills in this undated illustration. Eli Lilly/Handout via REUTERS
April 14 (Reuters) - The U.S. Food and Drug Administration said Eli Lilly is required to conduct post-marketing trials to gauge risks for liver injury, cardiovascular events, gastric emptying and a milk-only lactation study related to its newly approved obesity pill.
Advertisement
(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
Source: “AOL Breaking”
